Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2020-07-16 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Imugene Receives Second PD1-VAXX Ethics Trial Approval 3 pages 153.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited regarding receiving ethics approval to start a Phase I clinical trial for a new cancer immunotherapy. It discusses clinical trial details, regulatory approvals, and upcoming patient screening. There are no financial statements, earnings data, or detailed financial analysis. The content is an update on clinical trial progress and regulatory approvals, typical of a Capital/Financing Update or Regulatory Filing. However, since it is an announcement about clinical trial ethics approval and not about financing or capital structure changes, it fits best under Regulatory Filings (RNS) as a general regulatory announcement. The document length is about 5207 characters, which is sufficient for a full announcement but does not contain financial data or report content. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-07-16 English
Imugene Receives Ethics Approval to Start PD1-VAXX Trial 3 pages 153.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited about receiving ethics approval to start a Phase I clinical trial for a new cancer immunotherapy. It details the clinical trial initiation, regulatory approvals, and study objectives. There are no financial statements, earnings data, or management discussion of financial results. The content is an update on clinical trial progress and regulatory approval, which fits the category of a general regulatory announcement rather than a financial report or management report. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. Therefore, the best classification is Regulatory Filings (RNS).
2020-07-13 English
New mimotope cancer vaccine results published 2 pages 146.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited dated 28 May 2020. It discusses the publication of new preclinical research results related to a cancer vaccine, specifically mentioning the acceptance and publication of the research in a scientific journal. The content focuses on announcing the research findings and the company's development pipeline, rather than providing detailed financial data, management discussion, or regulatory filings. The document is relatively short (4643 characters) and serves as a news release about scientific progress and company strategy. It does not contain financial statements, voting results, or detailed management reports. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories like Annual Report, Earnings Release, or Investor Presentation.
2020-05-27 English
Release of Securities from Escrow 1 page 265.8KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement regarding the release of ordinary shares from escrow, referencing ASX listing rule 3.10A. It is a brief notice about share release, which relates to changes in share capital or shareholding status. The document length is short (732 characters), and it does not contain financial statements or detailed financial data. This fits the category of Share Issue/Capital Change (SHA) as it concerns the release of shares from escrow, a capital structure event.
2020-05-14 English
Imugene HER-Vaxx Phase 2 Clinical Update 3 pages 112.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 4 May 2020 from Imugene Limited regarding a Phase 2 clinical update on their HER-Vaxx cancer immunotherapy. It discusses the Independent Data Monitoring Committee's review and recommendation to continue the study without modification, along with some background on the study design and the company's immunotherapy platform. There are no financial statements, earnings data, or detailed financial analysis present. The document is a clinical trial progress update rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information about the clinical trial status. The content fits best under a general regulatory announcement category as it provides an update on clinical trial progress and safety review, which is typical for Regulatory Filings (RNS).
2020-05-03 English
IMU Presents PD1-Vaxx Clinical Plan at AACR Annual Meeting 2 pages 137.0KB
Investor Presentation Classification · 85% confidence The document is an ASX announcement from Imugene Limited about a presentation of their clinical plan for PD1-Vaxx at the American Association for Cancer Research 2020 Annual Meeting. It describes the event, the abstract, and the clinical trial details but does not contain financial data, earnings, or regulatory filings. The document is an announcement of a presentation at a scientific conference, not a financial report or regulatory filing. It is not an Annual Report, Earnings Release, or any other financial document type. Given the content and context, the best fitting category is Investor Presentation (IP), as it is a detailed presentation for investors focusing on clinical and strategic information about the company's product pipeline and clinical plans.
2020-04-26 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.